糖尿病脂代谢紊乱地治疗与临床指南.pptVIP

Clinical Trials and Guidelines for Lipid Management in the Diabetic PatientSteven Haffner, MD UKPDS Design UKPDS 10-Year Follow-up Results:Glycemic Control, Weight, and Plasma Insulin UKPDS: Proportion of Patients Taking Different Therapies in the Conventional-Therapy Group UKPDS: Causes of Death by Glucose Treatment Group UKPDS: Endpoints by Glucose Treatment Group UKPDS: Impact of Glucose-Lowering Agents on MI and Stroke UKPDS Results: Intensive Blood Pressure Control Comparison of Captopril vs. Atenolol in UKPDS Comparison of Glucose Lowering and Blood Pressure Lowering in UKPDS Treatment Strategies for Diabetic Dyslipidemia CHD Prevention Trials with Statins in Diabetic Subjects: Subgroup Analyses CHD Prevention Trials with Statins in Diabetic Subjects: Subgroup Analyses (cont’d) Diabetic vs. Nondiabetic Patients in 4S Major Coronary Events in 4S Patients with or without Diabetes by History (n=202) 4S: Extended Diabetic Subgroup Analysis: Diabetes (n=483; 251 on Simvastatin) — Fasting Glucose 7 mmol/L (126 mg/dl) 4S: Extended Diabetic Subgroup Analysis:Impaired Fasting Glucose (n=678; 343 on Simvastatin) — Fasting Glucose 6.0-6.9 mmol/L (110-125 mg/dl) 4S: Effect of Statin Therapy on Hospital Stay CARE: Major Coronary Events in Diabetic Subgroups AFCAPS/TexCAPS: Subgroup Analysis CARE: Major Coronary Events in Diabetic Subgroups POST-CABG: Effect of Aggressive Lipid Lowering on Progression in a Diabetic Subgroup CHD Prevention Trials with Fibrates in Diabetic Subjects: Subgroup Analyses Primary CHD* Prevention in Type 2 Diabetic Patients: The Helsinki Heart Study VA-HIT: Incidence of Death from CHD and Nonfatal MI VA-HIT: Death Due to CHD, Nonfatal MI, and Confirmed Stroke in Diabetic Patients Future Directions Heart Protection Study Endpoint Studies: Treating to New Targets (TNT): Study Design Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine with Simvastatin and Folic Acid/Vitamin B12 (SEARCH): Study Desi